参考文献/References:
[1] 王品，王雪娇．TKI 时代造血干细胞移植在慢性粒细胞白血病治疗中的地位[J]．重庆医学，2018，47（22）：2956-2958，2962． WANG Pin, WANG Xuejiao. Role of hematopoieticstem cell transplantation in the treatment of chronicmyelogenous leukemia in the TKI era [J]. ChongqingMedical Science,2018,47(22):2956-2958,2962
[2] 陈晓鹏，曹真睿，胡晶．慢性髓系白血病异基因造血干细胞移植的研究进展[J]．中国实验血液学杂志，2019，27（4）：1334-1338． CHEN Xiaopeng, Cao Zhenrui, Hu Jing.Advances inallogeneic hematopoietic stem cell transplantation forchronic myelogenous leukemia-Review [J].Journal ofExperimental hematology,2019,27(4):1334-1338.
[3] MIURA M. Therapeutic drug monitoring of imatinib,nilotinib, and dasatinib for patients with chronicmyeloid leukemia[J]. Biological & PharmaceuticalBulletin, 2015, 38(5): 645-654.
[4] YU Huixin, STEEGHS N, NIJENHUIS C M, et al.Practical guidelines for therapeutic drug monitoring
[8] VERHEIJEN R B, YU H, SCHELLENS J M, etal. Practical recommendations for therapeutic drugmonitoring of kinase inhibitors in oncology[J]. ClinicalPharmacology & Therapeutics, 2017, 102(5): 765.
[9] LYNCH K L. CLSI C62-A: A new standard for clinical massspectrometry[J]. Clinical Chemistry, 2016, 62(1): 24-29.
[10] 闫美玲，张萌，黄琳，等．BCR-ABL 35INS 突变型慢性粒细胞白血病患者选用酪氨酸激酶抑制剂的文献分析[J]．中国药房，2019，30（12）：1675-1678. YAN Meiling, ZHANG Meng, HUANG Lin, etal. Literature analysis of the selection of tyrosinekinase inhibitors for chronic myeloid leukemiapatients with BCR-ABL 35INS mutation[J]. ChinesePharmacy,2019,30(12):1675-1678.
[11] 扈臣媛，于迪，张兵，等．酪氨酸激酶抑制剂治疗12 个月的慢性髓系白血病患者BCR-ABLIS 与预后的关系及影响因素研究[J]．中国实验血液学杂志，2018,26（5）：1281-1287． HU Chenyuan, YU Di,ZHANG B i n g , e t a l .Relationship between BCR-ABLIS and prognosis andaffecting factors for prognosis in CML patients treatedwith TKI for 12 months [J]. Journal of ExperimentalHematology,2018,26,(5):1281-1287.
[12] BACCARANI M, CORTES J, PANE F, et al. Chronicmyeloid leukemia:an update of concepts and managementrecommendations of European LeukemiaNet[J].Journal of Clinical Oncology, 2009, 27(35): 6041-6051.
[13] 王磊，周枫叶，姜春菲，等．HPLC-MS ／ MS 法测定白血病患者血浆伊马替尼与达沙替尼浓度[J]．现代检验医学杂志，2016,31（1）：128-131． WANG Lei,ZHOU Fengye, JIANG Chunfei, et al.Determination of imatinib and dasatinib in leukemiapatients plasma by HPLC-MS /MS [J]. J Mod LabMed,2016,31(1):128-131.of anticancer tyrosine kinase inhibitors: focus on thepharmacokinetic targets[J]. Clinical Pharmacokinetics,2014, 53(4): 305-325.
[5] National Comprehensive Cancer Network. Clinicalpractice guidelines in oncology: chronic myeloidleukemia: Version2, 2017[S]. NCCN,2017-01-19.
[6] 金洁，阴秀峰．慢性髓性白血病患者BCR-ABL 激酶区突变的检测及临床意义[J]．中华血液学杂志，2014，35（2）：95-97． JIN Jie, YIN Xiufeng. Clinical significance of analysisof BCR-ABL kinase domain mutation in chronicmyeloid leukemia patients [J]. Chinese Journal ofHematology,2014,35(2):95-97.
[7] Food and Drug Administration. Center for drugevaluation and research, application number:203469Orig1s000, Clinical Pharmacology andBiopharmaceutics Review (2012). （下转52 页）